Johnson & Johnson's most recent trend suggests a bearish bias. One trading opportunity on Johnson & Johnson is a Bear Call Spread using a strike $90.00 short call and a strike $95.00 long call offers a potential 21.07% return on risk over the next 23 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $90.00 by expiration. The full premium credit of $0.87 would be kept by the premium seller. The risk of $4.13 would be incurred if the stock rose above the $95.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Johnson & Johnson is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Johnson & Johnson is bearish.
The RSI indicator is at 20.25 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Johnson & Johnson
Cramer grades the Dow
Thu, 30 Jan 2014 23:25:00 GMT
CNBC – Mad Money host Jim Cramer explains what earnings season means for the Dow by digging into the earnings of JPMorgan, American Express, DuPont and more.
Johnson & Johnson Announces Clinical Trial Data Sharing Agreement with Yale School of Medicine
Thu, 30 Jan 2014 12:40:35 GMT
noodls – NEW BRUNSWICK, January 30, 2014 – Johnson & Johnson today announced that its subsidiary, Janssen Research and Development, LLC, has entered into a novel agreement with Yale School of Medicine's Open Data …
[$$] J&J to Share Drug Research Data in Pact With Yale
Thu, 30 Jan 2014 05:57:53 GMT
The Wall Street Journal – J&J signed an agreement with Yale University under which it will share detailed clinical trial data from hundreds of drugs and other products with outside academic researchers.
J&J chooses Yale to review requests for clinical drug data
Thu, 30 Jan 2014 05:01:00 GMT
Reuters – UK Focus – Johnson & Johnson has selected the Yale School of Medicine to review requests from investigators and physicians looking for access to clinical trial data involving the diversified healthcare company's …
J&J chooses Yale to review requests for clinical drug data
Thu, 30 Jan 2014 05:01:00 GMT
Reuters – Johnson & Johnson has selected the Yale School of Medicine to review requests from investigators and physicians looking for access to clinical trial data involving the diversified healthcare company's pharmaceuticals. Under the agreement, the “Yale Open Data Access Project,” will independently review and make final decisions regarding all requests for information on the company's drug clinical trials, including anonymous patient data. The action comes amid growing pressure from outside scientists for access to raw data from clinical trials, reflecting general concerns that too many studies cannot be independently confirmed and may well be wrong. Britain's GlaxoSmithkline Plc has set up an online system to provide researchers with access to anonymous patient-level data about its medicines.
Related Posts
Also on Market Tamer…
Follow Us on Facebook